FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
10/03/2023
Back to search
Official data from USPTO
PHARMACT
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
PHARMACT
ST13
US500000079328751Class
5, 10, 42, 44
Filing
79328751
Registration
7039125
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
33
Latest update
10/03/2023
Trademark type
Word
Nice classes
5, 10, 42, 44
Filing date
09/03/2021
Registration date
05/02/2023
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
05/02/2023
Last transaction
05/02/2023
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
84
Owner location
CH
Examiner
MESSICK, TABITHA
Law office
L40
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Pharmact Holding AG
R. B. (pessoa física)
Representatives
Brian P. Gregg McNees Wallace & Nurick
Technical classification
Nice Classes
Class 5Class 10Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
medicines for human purposes for the treatment or prophylaxis of the nervous systemfor treatment or prophylaxis of the endocrine systemfor treatment or prophylaxis of cardiovascular systeminjectable pharmaceutical for treatment or prophylaxis of respiratory tractinjectable pharmaceutical for treatment or prophylaxis of gastro intestinal tractinjectable pharmaceutical for treatment or prophylaxis of kidney or urinary tractinjectable pharmaceutical for treatment or prophylaxis of skininjectable vitaminsinjectable antibioticsinjectable synthetic chemotherapeutic agentsinjectable antimyoticsinjectable pharmaceuticals for treatment or prophylaxis of mycobacteriainjectable pharmaceuticals for treatment or prophylaxis of parasitesinjectable pharmaceuticals for treatment or prophylaxis of virus infectionsinjectable cytokine agentsinjectable disinfectantinjectable pharmaceuticals for treatment of malignant tumorsinjectable pharmaceuticals for treatment of or prophylaxis of extracellular matrixinjectable pharmaceutical for treatment or prophylaxis of a hyaluronan-associated and proteoglycan-associated disease or disorder; pharmaceuticalsinjectable pharmaceutical for treatment or prophylaxis of homozygous familial hypercholesterolemiaof heterozygous familial hypercholesterolemiaof diabetic foot syndromeof arterial hypertension or cardiac insufficiency; pharmaceuticalsinjectable pharmaceutical for treatment or prophylaxis of a neurodegenerative disease associated with an increased cerebral glycosaminoglycan levelinjectable pharmaceutical for treatment or prophylaxis of Alzheimer's diseaseof vascular dementiaof Parkinson's diseaseof multiple sclerosisof amyotrophic lateral sclerosisof cerebral insultof brain traumaof cerebral inflammationsof autoimmune encephalitis; pharmaceuticalsinjectable pharmaceutical for treatment or prophylaxis of radiation diseaseinjectable pharmaceutical for treatment or prophylaxis of tendovaginitisof enthesiopathyof insertion tendinosisof insertion tendinopathyof tendonitisof periarthritisof periathrosisof arthrosisof osteoarthrosisof fibrosisof renal fibrosisof liver fibrosisof cardiac fibrosisof cardiac valve fibrosisof pulmonary fibrosisof pulmonary cirrhosisof pulmonary sclerosisof cerebral insultof cerebral strokeof apoplectic insultof apoplexia cerebriof ictus apoplecticusof cerebral infarctionof brain scarsof gliosisof contractureof fibrotendinous contractureof fibrous contractureof joint contractureof tendon contractureof Dupuytren's contractureof Dupuytren's diseaseof Dupuytren's contractureof glaucomaof eye pressure elevationof intraocular pressure elevationof primary chronic glaucomaof Multiple sclerosisof disseminated demyelinating encephalomyelitisof encephalomyelitis disseminataof encephalitis disseminataof cerebral polysclerosisof amyotrophic lateral sclerosisof myatrophic lateral sclerosisof motoneuron diseaseof Lou Gehrig's syndromeof postcovid syndromeof longcovid syndrome; cardiovascular agents for medical purposes; pharmaceutical preparations for treating hypertension; cardiovascular drugs used in angina pectorisdrug delivery agents in the form of tabletscapsulesspraysinjections that provide controlled release of active ingredients for use in treating angina pectoris; cardiovascular drugsdrug delivery agents in the form of tabletscapsulesspraysinjectionsthat provide controlled release of active ingredients for use in treating congestive heart failure; cardiovascular drugsdrug delivery agents in the form of tabletscapsulesspraysinjections that provide controlled release of active ingredients for use in myocardial infarction; pharmaceutical preparations for the treatment of heart rhythm disorders; antiseptics; anti-inflammatory preparations; pharmaceuticals for the treatment of erectile dysfunction; pharmaceutical preparations for the treatment of disorders of the metabolic system; pharmaceutical preparations for the prevention of diabetes; pharmaceutical preparations for the treatment of parkinson's disease; pharmaceutical preparations for the treatment of kidney diseases; anti-cancer drugspharmaceutical products for the prevention and treatment of cancer; biopharmaceuticals for the treatment of cancer; pharmaceutical preparations for the treatment of central nervous system diseases; pharmaceutical preparations for use in ophthalmology; amino acid preparations for medical purposes; pharmaceutical preparations for treating hypoglycemia; pharmaceutical preparations for the treatment of osteoporosis; pharmaceutical preparations for activating cellular function; drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; pharmaceutical preparations for the treatment of musculo-skeletal disorders; ferments for medical or veterinary use; eye bandages for medical use; living cells for medical use; pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; pharmaceutical preparations for treating asthma; pharmaceutical preparations for treating arthritis; pharmaceutical preparations for the treatment of hyperlipidemia; medicines for dental purposes; diagnostic preparations for medical or veterinary purposes; diagnostic agents for medical pharmaceutical use; biological indicators for medical diagnosis; diagnostic reagents for medical use; diagnostic biomarker reagents for medical purposes; clinical diagnostic reagents for medical use; in vitro diagnostic preparations for medical use; reagents for in-vitro laboratory use for medical purposes; immunoassay reagents for medical use; medical diagnostic test strips for detection of h-FABP being Heart-type Fatty Acid-Binding protein in the diagnosis of myocardial infarctfor detection of cTnI being Troponin I in the diagnosis of myocardial infarctfor detection of SARS-CoV-2 antigen in the diagnosis of Corona diseasefor detection of proinsulin for diagnosis of humans with abnormal insulin secretionfor the detection of YKL-40 being CHI3L1 protein for diagnosis and treatment of liver fibrosis; test strips for measuring blood glucose levels; impregnated medicated swabs; wadding for medical purposes; swabs for medical use; cellulose wadding for medical purposes; tampons for medical purposes; reagent paper for medical or veterinary purposes; impregnated pre-moistened medicated wipes; mouthwashes for medical purposes
Class 10
Medical diagnostic apparatus for testing for viruses; medical apparatus for analysing bacteria in biological samples; medical instruments for infectious disease testing; medical diagnostic testing instruments for use in immunoassay procedure; genetic testing apparatus for medical purposes; medical devices for obtaining body fluid samplesmeters for body fluids; medical test kits for diabetes monitoring for home use; medical apparatus for diagnosing suspected heart attacks; apparatus for DNA and RNA testing for medical purposes; chromatographic instruments for medical use for detection of h-FABP being Heart-type Fatty Acid-Binding protein in the diagnosis of myocardial infarctfor detection of cTnI being Troponin I in the diagnosis of myocardial infarctfor detection of SARS-CoV-2 antigen in the diagnosis of Corona diseasefor detection of proinsulin for diagnosis of humans with abnormal insulin secretionfor the detection of YKL-40 being CHI3L1 protein for diagnosis and treatment of liver fibrosis; diagnostic measuring apparatus for medical use for detection of h-FABP being Heart-type Fatty Acid-Binding protein in the diagnosis of myocardial infarctfor detection of cTnI being Troponin I in the diagnosis of myocardial infarctfor detection of SARS-CoV-2 antigen in the diagnosis of Corona diseasefor detection of proinsulin for diagnosis of humans with abnormal insulin secretionfor the detection of YKL-40 being CHI3L1 protein for diagnosis and treatment of liver fibrosis; diagnostic apparatus for medical purposesultrasound diagnostic apparatusdiagnostic apparatus for detection of cancerdiagnostic apparatus for detection of myocardial infarctdiagnostic apparatus for detection of cardiac rhythm disorderdiagnostic apparatus for detection of hypertensiondiagnostic apparatus for detection of liver fibrosisdiagnostic apparatus for detection of hypercholesterolemiadiagnostic apparatus for detection of heterozygous familial hypercholesterolemiadiagnostic apparatus for detection of diabetic foot syndromediagnostic apparatus for detection of Alzheimer's diseasediagnostic apparatus for detection of vascular dementiadiagnostic apparatus for detection of Parkinson's diseasediagnostic apparatus for detection of multiple sclerosisdiagnostic apparatus for detection of amyotrophic lateral sclerosisdiagnostic apparatus for detection of cerebral insultdiagnostic apparatus for detection of brain traumadiagnostic apparatus for detection of cerebral inflammationsdiagnostic apparatus for detection of autoimmune encephalitis; testing apparatus for medical purposes for testing blood sugar levelsfor testing cancer cellsfor testing DNA; protective face masks for medical use for anti bacterial protection; blood collection tubes for medical use; medical diagnostic saliva vials; temperature indicator labels for medical purposes; temperature measuring instruments for medical use in the nature of clinical thermometers; medical devicesreceptacles for applying medicines; patient monitoring instrumentsheart rate monitoring apparatus; containers especially made for medical waste; medical diagnostic testing instruments for use in immunoassay procedure; medical deviceimmunoadsorption columns for therapeutic use; specimen cup holders; gamma cameras for medical purposes; light sources for medical uselight emitting diode apparatus for lightingincorporated into medical instruments; lancets; measuring devices for medical use in the nature of devices for measuring woundsdevices for measuring blood sugar for medical purposes; blood lancets; pipetting instruments in the nature of dropping pipettes for medical use; blood glucose testing apparatus; medical deviceimmunoadsorption columns for diagnostic use; spittoons for medical purposes
Class 42
Pharmaceutical research and development; quality control for others; pharmaceutical product evaluation; consultancy pertaining to pharmacology; laboratory research services relating to pharmaceuticals
Class 44
Medical services; medical testing services relating to the diagnosis and treatment of disease; medical analysis for the diagnosis and treatment of persons; medical laboratory services for the analysis of samples taken from patients; medical analysis services for diagnostic and treatment purposes provided by medical laboratories; medical analysis services relating to the treatment of animals provided by medical laboratory; medical treatment services of treating myocardial infarcthypertensionliver fibrosishypercholesterolemiaheterozygous familial hypercholesterolemiadiabetic foot syndromeAlzheimer's diseasevascular dementiaParkinson's diseasemultiple sclerosisamyotrophic lateral sclerosiscerebral insultbrain traumacerebral inflammationsautoimmune encephalitis; medical testing for diagnostic or treatment purposes; medical services for the treatment of skin cancer; health care services for treating alzheimer's disease; medical analysis of human serum for medical treatment; providing information relating to the treatment of cardiovascular and cerebrovascular diseases via the internet; medical services relating to the removaltreatment and processing of human blood; medical services relating to the removaltreatment and processing of human cells; medical services in the nature of pharmacologicaltherapy services for treating myocardial infarcthypertensionliver fibrosishypercholesterolemiaheterozygous familial hypercholesterolemiadiabetic foot syndromeAlzheimer's diseasevascular dementiaParkinson's diseasemultiple sclerosisamyotrophic lateral sclerosiscerebral insultbrain traumacerebral inflammationsautoimmune encephalitis
Publications
History of USPTO decisions and trademark events.
33 publications found
XXSS
GENERIC MADRID TRANSACTION SENT TO IB
08/08/2023
XXCR
GENERIC MADRID TRANSACTION CREATED
08/08/2023
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
08/02/2023
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
05/02/2023
R.PR
REGISTERED-PRINCIPAL REGISTER
05/02/2023
GPNX
NOTIFICATION PROCESSED BY IB
02/14/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
02/14/2023
PUBO
PUBLISHED FOR OPPOSITION
02/14/2023
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
01/25/2023
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
01/25/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
01/25/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
01/12/2023
XAEC
EXAMINER'S AMENDMENT ENTERED
01/12/2023
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
01/12/2023
GNEA
EXAMINERS AMENDMENT E-MAILED
01/12/2023
CNEA
EXAMINERS AMENDMENT -WRITTEN
01/12/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
01/02/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
01/02/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
01/02/2023
RFNP
REFUSAL PROCESSED BY IB
07/26/2022
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
07/07/2022
RFRR
REFUSAL PROCESSED BY MPU
07/06/2022
CORR
CORRECTION FROM IB ENTERED - NO REVIEW REQUIRED
07/06/2022
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
06/19/2022
CNRT
NON-FINAL ACTION WRITTEN
06/18/2022
DOCK
ASSIGNED TO EXAMINER
06/09/2022
CRCV
CORRECTION TRANSACTION RECEIVED FROM IB
06/05/2022
CORR
CORRECTION FROM IB ENTERED - NO REVIEW REQUIRED
03/17/2022
CRCV
CORRECTION TRANSACTION RECEIVED FROM IB
02/19/2022
MAFR
APPLICATION FILING RECEIPT MAILED
12/22/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
12/18/2021
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
12/16/2021
Continuous trademark protection
Get notified about every new filing that threatens PHARMACT or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.